The epidemic of cardio-vascular disease in renal failure: Where does it come from, where do we go?

Acta Clinica Belgica

Volumn 61, Issue 5, 2006, Pages 205-211

  Vanholder, Raymond ^a   Van Biesen, W ^a   Verbeke, F ^a   Lameire, N ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cardiac morbidity; Cardiac mortality; Cardio vascular disease; Chronic kidney disease; Chronic renal failure; Uremia

Indexed keywords

ATHEROGENESIS; ATHEROMATOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIALYSIS; DISEASE ASSOCIATION; ECONOMIC ASPECT; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; PREVENTIVE MEDICINE; QUALITY OF LIFE; REVIEW; RISK FACTOR; UNITED STATES;

EID: 33845483457     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2006.035     Document Type: Review

References (63)

1. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999; 10(8):1815-23.
2. Moeller S, Gioberge S, Brown G. ESRD patients in 2001: global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant 2002; 17(12):2071.
3. Ritz E, McClellan WM. Overview: increased cardiovascular risk in patients with minor renal dysfunction: an emerging issue with far-reaching consequences. J Am Soc Nephrol 2004; 15(3):513-6.
4. Pinkau T, Hilgers KF, Veelken R, Mann JF. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? J Am Soc Nephrol 2004; 15(3):517-23.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340(2):115-26.
6. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32(5 Suppl 3):S112-9.
7. Stenvinkel P, Heimburger O, Paultre F, Diczfalusy U, Wang T, Berglund L et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55(5):1899-1911.
8. Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107(1):87-92.
9. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290(13):697-701.
10. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342(20):1478-83.
11. Iseki K, Fukiyama K. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. The Okinawa Dialysis Study Group. Am J Kidney Dis 2000; 36(4):820-25.
12. Pastan S, Bailey J. Dialysis therapy. N Engl J Med 1998; 338(20):1428-37.
13. Meier-Kriesche HU, Port FK, Ojo AO, Rudich SM, Hanson JA, Cibrik DM et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58(3):1311-7.
14. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4(10):1662-8.
15. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75(8):1291-5.
16. Shoji T, Emoto M, Tabata T, Kimoto E, Shinohara K, Maekawa K et al. Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int 2002; 61(6):2187-92.
17. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20(6):1048-56.
18. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13(3):745-53.
19. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63(3):1121-9.
20. Manjunath G, Tighiouart H, Ibrahim H, Macleod B, Salem DN, Griffith JL et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41(1):47-55.
21. Reddan DN, Szczech LA, Tuttle RH, Shaw LK, Jones RH, Schwab SJ et al. Chronic kidney disease, mortality, and treatment strategies among patients with clinically significant coronary artery disease. J Am Soc Nephrol 2003; 14(9):2373-80.
22. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13):1296-1305.
23. Wang JG, Staessen JA, Fagard RH, Birkenhager WH, Gong L, Liu L. Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. Hypertension 2001; 37(4):1069-74.
24. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003; 41(1):1-12.
25. Chadban SJ, Briganti EM, Kerr PG, Dunstan DW, Welborn TA, Zimmet PZ et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol 2003; 14(7 Suppl 2):S131-S8.
26. Simal F, Martin Escudero JC, Bellido J, Arzua D, Mena FJ, Gonzalez M, I et al. [Prevalence of mild to moderate chronic kidney disease in the general population of Spain. Hortega study]. Nefrologia 2004; 24(4)329-37.
27. John R, Webb M, Young A, Stevens PE. Unreferred chronic kidney disease: a longitudinal study. Am J Kidney Dis 2004; 43(5):825-35.
28. Magnason RL, Indridason OS, Sigvaldason H, Sigfusson N, Palsson R. Prevalence and progression of CRF in Iceland: a population-based study. Am J Kidney DB 2002; 40(5):955-63.
29. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414(6865):782-7.
30. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286(4):421-6.
31. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in the general population. Circulation 2002; 106(14):1777-82.
32. McCullough PA, Sandberg KR, Borzak S, Hudson MP, Garg M, Manley HJ. Benefits of aspirin and beta-blockade after myocardial infarction in patients with chronic kidney disease. Am Heart J 2002; 144(2):226-32.
33. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002; 137(7):555-62.
34. Lameire N, Wauters JP, Teruel JL, Van Biesen W, Vanholder R. An update on the referral pattern of patients with end-stage renal disease. Kidney Int Suppl 2002;(80):27-34.
35. Lameire N, Van Biesen W. The pattern of referral of patients with end-stage renal disease to the nephrologist-a European survey. Nephrol Dial Transplant 1999; 14 Suppl 6:16-23.
36. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J et al. Definition and classification of chronic kidney disease: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67(6):2089-100.
37. Fleischmann EH, Bower JD, Salahudeen AK. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients? Clin Nephrol 2001; 56(3):221-30.
38. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63(3):793-808.
39. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61(4):1486-94.
40. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58(1):353-62.
41. Vanholder R, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G et al. Uremic toxicity: present state of the art. Int J Artif Organs 2001; 24(10):695-725.
42. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13(1):170-6.
43. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324(17):1149-55.
44. Glorieux GL, Dhondt AW, Jacobs P, Van Langeraert J, Lameire NH, De Deyn PP et al. In vitro study of the potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 2004; 65(6):2184-92.
45. Perna AF, Ingrosso D, Satta E, Lombardi C, Galletti P, D'Aniello A et al. Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences. J Am Soc Nephrol 2004; 15(10):2747-54.
46. Jankowski J, Van der GM, Jankowski V, Schmidt S, Hemeier M, Mahn B et al. Increased plasma phenylacetic acid in patients with end-stage renal failure inhibits iNOS expression. J Clin Invest 2003; 112(2):256-64.
47. Jankowski J, Tepel M, Stephan N, Van der GM, Breden V, Zidek W et al. Characterization of p-hydroxy-hippuric acid as an inhibitor of Ca2+-ATPase in end-stage renal failure. Kidney Int Suppl 2001; 78:S84-S8.
48. Glorieux G, Helling R, Henle T, Brunet P, Deppisch R, Lameire N et al. In vitro evidence for immune activating effect of specific ACE structures retained in uremia. Kidney Int 2004; 66(5):1873-80.
49. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65(2):442-51.
50. Cerini C, Dou L, Anfosso F, Sabatier F, Moal V, Glorieux G et al. P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 2004; 92(1):140-50.
51. Canalejo A, Almaden Y, De Smet R, Glorieux G, Garfia B, Luque F et al. Effects of uremic ultrafiltrate on the regulation of the parathyroid cell cycle by calcitriol. Kidney Int 2003; 63(2):732-7.
52. Jankowski V, Tolle M, Vanholder R, Schonfelder G, Van der GM, Henning L et al. Uridine adenosine tetraphosphate: a novel endothelium- derived vasoconstrictive factor. Nat Med 2005; 11(2):223-7.
53. Jankowski J, Jankowski V, Laufer U, Van der GM, Henning L, Tepel M et al. Identification and quantification of diadenosine polyphosphate concentrations in human plasma. Arterioscler Thromb Vasc Biol 2003; 23(7):1231-8.
54. Jankowski J, Schluter H, Henning L, Van der GM, Jankowski V, Zidek W et al. The AN69 hemofiltration membrane has a decreasing effect on the intracellular diadenosine pentaphosphate concentration of platelets. Kidney Blood Press Res 2003; 26(1):50-4.
55. Weissinger EM, Kaiser T, Meert N, De Smet R, Walden M, Mischak H et al. Proteomics: a novel tool to unravel the patho-physiology of uraemia. Nephrol Dial Transplant 2004; 19(12):3068-77.
56. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P et al. Review on ure;mic toxins: classification, concentration, and interindividual variability. Kidney Int 2003; 63(5):1934-43.
57. Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W. Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int 2003; 64(2):610-5.
58. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31(4):607-17.
59. Yango A, Shemin D, Hsu N, Jacques PF, Dworkin L, Selhub J et al. Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Kidney Int 2001; 59(1):324-7.
60. Rahmati MA, Craig RG, Homel P, Kaysen GA, Levin NW. Serum markers of periodontal disease status and inflammation in hemodialysis patients. Am J Kidney Dis 2002; 40(5):983-9.
61. Vanholder RC, Ringoir SM. Adequacy of dialysis: a critical analysis. Kidney Int 1992; 42(3):540-58.
62. Boure T, Vanholder R. Which dialyser membrane to choose? Nephrol Dial Transplant 2004; 19(2):293-6.
63. Wieslander A, Linden T, Musi B, Carlsson O, Deppisch R. Biological significance of reducing glucose degradation products in peritoneal dialysis fluids. Perit Dial Int 2000; 20 Suppl 5:S23-S7.